9. REFERENCES
1.Rouprêt, M., et al., Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma. In: EAU Guidelines published at the 38th Annual Congress Milan 2023. European Associaton of Urology Guidelines Office, Arnhem, the Netherlands.
https://uroweb.org/guidelines/upper-urinary-tract-urothelial-cell-carcinoma
2.Gontero, P., et al. Guidelines on Non-muscle-invasive bladder cancer (Ta, T1 and CIS). In: EAU Guidelines published at the 38th Annual Congress Milan 2023. European Associaton of Urology Guidelines Office, Arnhem, the Netherlands.
https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer
3.Gakis, G., et al. EAU Guidelines on Primary Urethral Carcinoma. In: EAU Guidelines published at the 38th Annual Congress Milan 2023. European Associaton of Urology Guidelines Office, Arnhem, the Netherlands.
https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer
4.Witjes, J.A., et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol, 2021. 79: 82.
https://pubmed.ncbi.nlm.nih.gov/32360052/
5.Guyatt, G.H., et al. What is “quality of evidence” and why is it important to clinicians? BMJ, 2008. 336: 995.
https://pubmed.ncbi.nlm.nih.gov/18456631/
6.Guyatt, G.H., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008. 336: 924.
https://pubmed.ncbi.nlm.nih.gov/18436948/
7.Phillips B, et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. Access date February 2023.
8.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.
https://pubmed.ncbi.nlm.nih.gov/18467413/
9.Horwich, A., et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. Ann Oncol, 2019. 30: 1697.
https://pubmed.ncbi.nlm.nih.gov/31740927/
10.Witjes, J.A., et al. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort(†): Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol, 2020. 77: 223.
https://pubmed.ncbi.nlm.nih.gov/31753752/
11.IARC. Estimated number of new cases in 2020, worldwide, both sexes, all ages. 2020. Access date December 2022.
https://gco.iarc.fr/today/online-analysis-multi-bars
12.Burger, M., et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol, 2013. 63: 234.
https://pubmed.ncbi.nlm.nih.gov/22877502/
13.Bosetti, C., et al. Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol, 2011. 60: 1.
https://pubmed.ncbi.nlm.nih.gov/21497988/
14.Teoh, J.Y., et al. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. Eur Urol, 2020. 78: 893.
https://pubmed.ncbi.nlm.nih.gov/32972792/
15.Chavan, S., et al. International variations in bladder cancer incidence and mortality. Eur Urol, 2014. 66: 59.
https://pubmed.ncbi.nlm.nih.gov/24451595/
16.Comperat, E., et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch, 2015. 466: 589.
https://pubmed.ncbi.nlm.nih.gov/25697540/
17.Freedman, N.D., et al. Association between smoking and risk of bladder cancer among men and women. JAMA, 2011. 306: 737.
https://pubmed.ncbi.nlm.nih.gov/21846855/
18.van Osch, F.H., et al. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol, 2016. 45: 857.
https://pubmed.ncbi.nlm.nih.gov/27097748/
19.Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum, 2004. 83: 1.
https://pubmed.ncbi.nlm.nih.gov/15285078/
20.Brennan, P., et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer, 2000. 86: 289.
https://pubmed.ncbi.nlm.nih.gov/10738259/
21.Gandini, S., et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer, 2008. 122: 155.
https://pubmed.ncbi.nlm.nih.gov/17893872/
22.Al Hussein Al Awamlh, B., et al. Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study. J Urol, 2019. 202: 1248.
https://pubmed.ncbi.nlm.nih.gov/31290707/
23.Zhang, Y., et al. Personal use of permanent hair dyes and cancer risk and mortality in US women: prospective cohort study. BMJ, 2020. 370: m2942.
https://pubmed.ncbi.nlm.nih.gov/32878860/
24.Pashos, C.L., et al. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract, 2002. 10: 311.
https://pubmed.ncbi.nlm.nih.gov/12406054/
25.Chrouser, K., et al. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol, 2005. 174: 107.
https://pubmed.ncbi.nlm.nih.gov/15947588/
26.Harling, M., et al. Bladder cancer among hairdressers: a meta-analysis. Occup Environ Med, 2010. 67: 351.
https://pubmed.ncbi.nlm.nih.gov/20447989/
27.Weistenhofer, W., et al. N-acetyltransferase-2 and medical history in bladder cancer cases with a suspected occupational disease (BK 1301) in Germany. J Toxicol Environ Health A, 2008. 71: 906.
https://pubmed.ncbi.nlm.nih.gov/18569594/
28.Rushton, L., et al. Occupation and cancer in Britain. Br J Cancer, 2010. 102: 1428.
https://pubmed.ncbi.nlm.nih.gov/20424618/
29.Nieder, A.M., et al. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol, 2008. 180: 2005.
https://pubmed.ncbi.nlm.nih.gov/18801517/
30.Zelefsky, M.J., et al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys, 2012. 83: 953.
https://pubmed.ncbi.nlm.nih.gov/22172904/
31.Zamora-Ros, R., et al. Flavonoid and lignan intake in relation to bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Br J Cancer, 2014. 111: 1870.
https://pubmed.ncbi.nlm.nih.gov/25121955/
32.Teleka, S., et al. Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: A prospective pooled cohort study of 800,000 men and women. Int J Cancer, 2018. 143: 3071.
https://pubmed.ncbi.nlm.nih.gov/29756343/
33.Xu, Y. Diabetes mellitus and the risk of bladder cancer: A PRISMA-compliant meta-analysis of cohort studies. Medicine (Baltimore). 2017. 96: e8588.
https://pubmed.ncbi.nlm.nih.gov/29145273/
34.Adil, M., et al. Pioglitazone and risk of bladder cancer in type 2 diabetes mellitus patients: A systematic literature review and meta-analysis of observational studies using real-world data. Clin Epidemiol Global Health, 2018. 6: 61.
https://www.sciencedirect.com/science/article/abs/pii/S2213398417300544
35.FDA Drug Safety Podcast: Updated FDA review concludes that use of pioglitazone may be linked to an increased risk of bladder cancer. 2016. Access date February 2023.
36.Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum, 1994. 61: 1.
https://pubmed.ncbi.nlm.nih.gov/7715068/
37.Gouda, I., et al. Bilharziasis and bladder cancer: a time trend analysis of 9843 patients. J Egypt Natl Canc Inst, 2007. 19: 158.
https://pubmed.ncbi.nlm.nih.gov/19034337/
38.Salem, H.K., et al. Changing patterns (age, incidence, and pathologic types) of schistosoma-associated bladder cancer in Egypt in the past decade. Urology, 2012. 79: 379.
https://pubmed.ncbi.nlm.nih.gov/22112287/
39.Pelucchi, C., et al. Mechanisms of disease: The epidemiology of bladder cancer. Nat Clin Pract Urol, 2006. 3: 327.
https://pubmed.ncbi.nlm.nih.gov/16763645/
40.Bayne, C.E., et al. Role of urinary tract infection in bladder cancer: a systematic review and meta-analysis. World J Urol, 2018. 36: 1181.
https://pubmed.ncbi.nlm.nih.gov/29520590/
41.Yu, Z., et al. The risk of bladder cancer in patients with urinary calculi: a meta-analysis. Urolithiasis, 2018. 46: 573.
https://pubmed.ncbi.nlm.nih.gov/29305631/
42.Liu, S., et al. The impact of female gender on bladder cancer-specific death risk after radical cystectomy: a meta-analysis of 27,912 patients. Int Urol Nephrol, 2015. 47: 951.
https://pubmed.ncbi.nlm.nih.gov/25894962/
43.Waldhoer, T., et al. Sex Differences of >/= pT1 Bladder Cancer Survival in Austria: A Descriptive, Long-Term, Nation-Wide Analysis Based on 27,773 Patients. Urol Int, 2015. 94: 383.
https://pubmed.ncbi.nlm.nih.gov/25833466/
44.Krimphove, M.J., et al. Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. Eur Urol Focus, 2021. 7: 124.
https://pubmed.ncbi.nlm.nih.gov/31227463/
45.Patafio, F.M., et al. Is there a gender effect in bladder cancer? A population-based study of practice and outcomes. Can Urol Assoc J, 2015. 9: 269.
https://pubmed.ncbi.nlm.nih.gov/26316913/
46.Andreassen, B.K., et al. Bladder cancer survival: Women better off in the long run. Eur J Cancer, 2018. 95: 52.
https://pubmed.ncbi.nlm.nih.gov/29635144/
47.Cohn, J.A., et al. Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation. Cancer, 2014. 120: 555.
https://pubmed.ncbi.nlm.nih.gov/24496869/
48.Dietrich, K., et al. Parity, early menopause and the incidence of bladder cancer in women: a case-control study and meta-analysis. Eur J Cancer, 2011. 47: 592.
https://pubmed.ncbi.nlm.nih.gov/21067913/
49.Scosyrev, E., et al. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer, 2009. 115: 68.
https://pubmed.ncbi.nlm.nih.gov/19072984/
50.Stenzl, A. Words of wisdom. Re: sex and racial differences in bladder cancer presentation and mortality in the US. Eur Urol, 2010. 57: 729.
https://pubmed.ncbi.nlm.nih.gov/20965044/
51.Abufaraj, M., et al. The impact of hormones and reproductive factors on the risk of bladder cancer in women: results from the Nurses’ Health Study and Nurses’ Health Study II. Int J Epidemiol, 2020. 49: 599.
https://pubmed.ncbi.nlm.nih.gov/31965144/
52.Martin, C., et al. Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst, 2018. 110: 527.
https://pubmed.ncbi.nlm.nih.gov/29228305/
53.Murta-Nascimento, C., et al. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol Biomarkers Prev, 2007. 16: 1595.
https://pubmed.ncbi.nlm.nih.gov/17684133/
54.Figueroa, J.D., et al. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet, 2014. 23: 1387.
https://pubmed.ncbi.nlm.nih.gov/24163127/
55.Rothman, N., et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet, 2010. 42: 978.
https://pubmed.ncbi.nlm.nih.gov/20972438/
56.Kiemeney, L.A., et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet, 2008. 40: 1307.
https://pubmed.ncbi.nlm.nih.gov/18794855/
57.Varma, M., et al. Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol, 2020. 33: 700.
https://pubmed.ncbi.nlm.nih.gov/31685965/
58.Paner, G.P., et al. Further characterization of the muscle layers and lamina propria of the urinary bladder by systematic histologic mapping: implications for pathologic staging of invasive urothelial carcinoma. Am J Surg Pathol, 2007. 31: 1420.
https://pubmed.ncbi.nlm.nih.gov/17721199/
59.Weiner, A.B., et al. Tumor Location May Predict Adverse Pathology and Survival Following Definitive Treatment for Bladder Cancer: A National Cohort Study. Eur Urol Oncol, 2019. 2: 304.
https://pubmed.ncbi.nlm.nih.gov/31200845/
60.Stenzl, A. Current concepts for urinary diversion in women. Eur Urol (EAU Update series 1), 2003: 91.
https://www.infona.pl/resource/bwmeta1.element.elsevier-76dc31cc-6155-35b6-9e7a-9d277d5e662a
61.Varinot, J., et al. Full analysis of the prostatic urethra at the time of radical cystoprostatectomy for bladder cancer: impact on final disease stage. Virchows Arch, 2009. 455: 449.
https://pubmed.ncbi.nlm.nih.gov/19841937/
62.Hansel, D.E., et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol, 2013. 63: 321.
https://pubmed.ncbi.nlm.nih.gov/23088996/
63.Herr, H.W. Pathologic evaluation of radical cystectomy specimens. Cancer, 2002. 95: 668.
https://pubmed.ncbi.nlm.nih.gov/12209761/
64.Fajkovic, H., et al. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis. Eur Urol, 2013. 64: 837.
https://pubmed.ncbi.nlm.nih.gov/22877503/
65.Fritsche, H.M., et al. Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node-positive urothelial carcinoma. Eur Urol, 2013. 63: 739.
https://pubmed.ncbi.nlm.nih.gov/23079053/
66.Neuzillet, Y., et al. Positive surgical margins and their locations in specimens are adverse prognosis features after radical cystectomy in non-metastatic carcinoma invading bladder muscle: results from a nationwide case-control study. BJU Int, 2013. 111: 1253.
https://pubmed.ncbi.nlm.nih.gov/23331375/
67.Baltaci, S., et al. Reliability of frozen section examination of obturator lymph nodes and impact on lymph node dissection borders during radical cystectomy: results of a prospective multicentre study by the Turkish Society of Urooncology. BJU Int, 2011. 107: 547.
https://pubmed.ncbi.nlm.nih.gov/20633004/
68.Jimenez, R.E., et al. Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol, 2000. 24: 980.
https://pubmed.ncbi.nlm.nih.gov/10895820/
69.Veskimae, E., et al. What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. Eur Urol Oncol, 2019. 2: 625.
https://pubmed.ncbi.nlm.nih.gov/31601522/
70.Sjodahl, G., et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res, 2012. 18: 3377.
https://pubmed.ncbi.nlm.nih.gov/22553347/
71.Choi, W., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell, 2014. 25: 152.
https://pubmed.ncbi.nlm.nih.gov/24525232/
72.Sauter G, et al., Tumours of the urinary system: non-invasive urothelial neoplasias., In: WHO classification of tumors of the urinary system and male genital organs. 2004, IARCC Press: Lyon, France.
73.Moch, H., Classification of Tumours of the Urinary System and Male Genital Organs, 2016. IARC, Lyon, France.
74.WHO Classification of Tumours - Urinary and Male Genital Tumours, 2022. IARC, Lyon, France
75.Compérat, E., et al. What’s new in WHO fifth edition1398042195-1398042195urinary tract. Histopathology, 2022. 81: 439.
https://pubmed.ncbi.nlm.nih.gov/35942645/
76.Willis, D.L., et al. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol, 2015. 193: 1129.
https://pubmed.ncbi.nlm.nih.gov/25254936/
77.Compérat, E., et al. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology, 2010. 42: 650.
https://pubmed.ncbi.nlm.nih.gov/21080874/
78.Kaimakliotis, H.Z., et al. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm? Urol Oncol, 2014. 32: 833.
https://pubmed.ncbi.nlm.nih.gov/24954925/
79.Beltran, A.L., et al. Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Arch, 2014. 465: 199.
https://pubmed.ncbi.nlm.nih.gov/24878757/
80.Soave, A., et al. Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? Urol Oncol, 2015. 33: 21.e1.
https://pubmed.ncbi.nlm.nih.gov/25465301/
81.Masson-Lecomte, A., et al. Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy. World J Urol, 2015. 33: 1087.
https://pubmed.ncbi.nlm.nih.gov/25179011/
82.Seisen, T., et al. Impact of histological variants on the outcomes of nonmuscle invasive bladder cancer after transurethral resection. Curr Opin Urol, 2014. 24: 524.
https://pubmed.ncbi.nlm.nih.gov/25051021/
83.Willis, D.L., et al. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol, 2014. 32: 826.
https://pubmed.ncbi.nlm.nih.gov/24931270/
84.Brierley JD, TNM classification of malignant tumors. UICC International Union Against Cancer. 8th edn. 2016, Oxford, UK.
https://www.uicc.org/resources/tnm-classification-malignant-tumours-8th-edition
85.Jensen, J.B., et al. Incidence of occult lymph-node metastasis missed by standard pathological examination in patients with bladder cancer undergoing radical cystectomy. Scand J Urol Nephrol, 2011. 45: 419.
https://pubmed.ncbi.nlm.nih.gov/21767245/
86.Mariappan, P., et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int, 2012. 109: 1666.
https://pubmed.ncbi.nlm.nih.gov/22044434/
87.Compérat, E., et al. Dataset for the reporting of carcinoma of the bladder-cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Virchows Arch, 2020. 476: 521.
https://pubmed.ncbi.nlm.nih.gov/31915958/
88.Magers, M.J., et al. Clinicopathological characteristics of ypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. J Clin Pathol, 2019. 72: 550.
https://pubmed.ncbi.nlm.nih.gov/31164444/
89.Martini, A., et al. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. Cancer, 2019.
125: 3155.
https://pubmed.ncbi.nlm.nih.gov/31150110/
90.Fossa, S.D., et al. Clinical significance of the “palpable mass” in patients with muscle-infiltrating bladder cancer undergoing cystectomy after pre-operative radiotherapy. Br J Urol, 1991. 67: 54.
https://pubmed.ncbi.nlm.nih.gov/1993277/
91.Wijkstrom, H., et al. Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients. Br J Urol, 1998. 81: 686.
https://pubmed.ncbi.nlm.nih.gov/9634042/
92.Ploeg, M., et al. Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. Urol Oncol, 2012. 30: 247.
https://pubmed.ncbi.nlm.nih.gov/20451418/
93.Blick, C.G., et al. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int, 2012. 110: 84.
https://pubmed.ncbi.nlm.nih.gov/22122739/
94.Wong, V.K., et al. Imaging and Management of Bladder Cancer. Cancers, 2021. 13: 1396.
https://pubmed.ncbi.nlm.nih.gov/doi:10.3390/cancers13061396/
95.Lokeshwar, V.B., et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology, 2005. 66: 35.
https://pubmed.ncbi.nlm.nih.gov/16399415/
96.Raitanen, M.P., et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol, 2002. 41: 284.
https://pubmed.ncbi.nlm.nih.gov/12180229/
97.van Rhijn, B.W., et al. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol, 2005. 47: 736.
https://pubmed.ncbi.nlm.nih.gov/15925067/
98.The Paris System for Reporting Urinary Cytology. E.M. Wojcik, D.F.I. Kurtycz, D.L. Rosenthal, Eds. Springer Cham. 2022, Switzerland.
99.Mariappan, P., et al. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol, 2010. 57: 843.
https://pubmed.ncbi.nlm.nih.gov/19524354/
100.Stenzl, A., et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol, 2010. 184: 1907.
https://pubmed.ncbi.nlm.nih.gov/20850152/
101.Burger, M., et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol, 2013. 64: 846.
https://pubmed.ncbi.nlm.nih.gov/23602406/
102.Matzkin, H., et al. Transitional cell carcinoma of the prostate. J Urol, 1991. 146: 1207.
https://pubmed.ncbi.nlm.nih.gov/1942262/
103.Mungan, M.U., et al. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. Eur Urol, 2005. 48: 760.
https://pubmed.ncbi.nlm.nih.gov/16005563/
104.Kassouf, W., et al. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. J Urol, 2008. 180: 164.
https://pubmed.ncbi.nlm.nih.gov/18485384/
105.Walsh, D.L., et al. Dilemmas in the treatment of urothelial cancers of the prostate. Urol Oncol, 2009. 27: 352.
https://pubmed.ncbi.nlm.nih.gov/18439852/
106.Lebret, T., et al. Urethral recurrence of transitional cell carcinoma of the bladder. Predictive value of preoperative latero-montanal biopsies and urethral frozen sections during prostatocystectomy. Eur Urol, 1998. 33: 170.
https://pubmed.ncbi.nlm.nih.gov/9519359/
107.Donat, S.M., et al. The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer. J Urol, 2001. 165: 1580.
https://pubmed.ncbi.nlm.nih.gov/11342921/
108.von Rundstedt, F.C., et al. Transurethral biopsy of the prostatic urethra is associated with final apical margin status at radical cystoprostatectomy. J Clin Urol, 2016. 9: 404.
https://pubmed.ncbi.nlm.nih.gov/27818773/
109.Kates, M., et al. Accuracy of urethral frozen section during radical cystectomy for bladder cancer. Urol Oncol, 2016. 34: 532.e1.
https://pubmed.ncbi.nlm.nih.gov/27432433/
110.Comperat, E.M., et al. Grading of Urothelial Carcinoma and The New “World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016”. Eur Urol Focus, 2019. 5: 457.
https://pubmed.ncbi.nlm.nih.gov/29366854/
111.AJCC Cancer Staging Manual. 8th ed. 2017, Cham, Switzerland.
https://link.springer.com/book/9783319406176
112.Amin, M.B., et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin, 2017. 67: 93.
https://pubmed.ncbi.nlm.nih.gov/28094848/
113.Tan, W.S., et al. Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria? J Urol, 2018. 200: 973.
https://pubmed.ncbi.nlm.nih.gov/29702097/
114.Mallampati, G.K., et al. MR imaging of the bladder. Magn Reson Imaging Clin N Am, 2004. 12: 545.
https://pubmed.ncbi.nlm.nih.gov/15271370/
115.Rajesh, A., et al. Bladder cancer: evaluation of staging accuracy using dynamic MRI. Clin Radiol, 2011. 66: 1140.
https://pubmed.ncbi.nlm.nih.gov/21924408/
116.Huang, L., et al. The Diagnostic Value of MR Imaging in Differentiating T Staging of Bladder Cancer: A Meta-Analysis. Radiology, 2018. 286: 502.
https://pubmed.ncbi.nlm.nih.gov/29206594/
117.Cornelissen, S.W.E., et al. Diagnostic Accuracy of Multiparametric MRI for Local Staging of Bladder Cancer: A Systematic Review and Meta-Analysis. Urology, 2020. 145: 22.
https://pubmed.ncbi.nlm.nih.gov/32721515/
118.Panebianco, V., et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol, 2018. 74: 294.
https://pubmed.ncbi.nlm.nih.gov/29755006/
119.Del Giudice, F., et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol, 2020. 77: 101.
https://pubmed.ncbi.nlm.nih.gov/31699526/
120.Metwally, M.I., et al. The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study. Eur Radiol, 2021. 31: 6949.
https://pubmed.ncbi.nlm.nih.gov/33606105/
121.Arita, Y., et al. Diagnostic Value of the Vesical Imaging-Reporting and Data System in Bladder Urothelial Carcinoma with Variant Histology. Eur Urol Oncol, 2022.
https://pubmed.ncbi.nlm.nih.gov/35933266/
122.Bicchetti, M., et al. A novel pathway to detect muscle-invasive bladder cancer based on integrated clinical features and VI-RADS score on MRI: results of a prospective multicenter study. Radiol Med, 2022. 127: 881.
https://pubmed.ncbi.nlm.nih.gov/35763251/
123.Woo, S., et al. Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol, 2020. 3: 306.
https://pubmed.ncbi.nlm.nih.gov/32199915/
124.Del Giudice, F., et al. Systematic Review and Meta-Analysis of Vesical Imaging-Reporting and Data System (VI-RADS) Inter-Observer Reliability: An Added Value for Muscle Invasive Bladder Cancer Detection. Cancers (Basel), 2020. 12: 2994.
https://pubmed.ncbi.nlm.nih.gov/33076505/
125.Bryan, R.T., et al. Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. Eur Urol, 2021. 80: 12.
https://pubmed.ncbi.nlm.nih.gov/33653635/
126.Thomsen, H.S., ESUR Guidelines on Contrast Agents 10.0. 2018. Access date December 2022.
https://www.esur.org/esur-guidelines-on-contrast-agents/
127.Aslan, S., et al. Comparison of the diagnostic accuracy and validity of biparametric MRI and multiparametric MRI-based VI-RADS scoring in bladder cancer; is contrast material really necessary in detecting muscle invasion? Abdom Radiol (NY), 2022. 47: 771.
https://pubmed.ncbi.nlm.nih.gov/34919161/
128.Kundra, V., et al. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. AJR Am
J Roentgenol, 2003. 180: 1045.
https://pubmed.ncbi.nlm.nih.gov/12646453/
129.Kim, B., et al. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology, 1994. 193: 239.
https://pubmed.ncbi.nlm.nih.gov/8090898/
130.Paik, M.L., et al. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol, 2000. 163: 1693.
https://pubmed.ncbi.nlm.nih.gov/10799162/
131.Thomsen, H.S. Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am, 2009. 47: 827.
https://pubmed.ncbi.nlm.nih.gov/19744597/
132.Ito, Y., et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol, 2011. 185: 1621.
https://pubmed.ncbi.nlm.nih.gov/21419429/
133.Cowan, N.C., et al. Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int, 2007. 99: 1363.
https://pubmed.ncbi.nlm.nih.gov/17428251/
134.Messer, J.C., et al. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol, 2013.
31: 904.
https://pubmed.ncbi.nlm.nih.gov/21906967/
135.Hurel, S., et al. Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy. World J Urol, 2015. 33: 335.
https://pubmed.ncbi.nlm.nih.gov/24810657/
136.Verhoest, G., et al. Predictive factors of recurrence and survival of upper tract urothelial carcinomas. World J Urol, 2011. 29: 495.
https://pubmed.ncbi.nlm.nih.gov/21681525/
137.Takahashi, N., et al. Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J Urol, 2010. 183: 1330.
https://pubmed.ncbi.nlm.nih.gov/20171676/
138.Kim, J.K., et al. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology, 2004. 231: 725.
https://pubmed.ncbi.nlm.nih.gov/15118111/
139.Yang, W.T., et al. Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma. AJR Am J Roentgenol, 2000. 175: 759.
https://pubmed.ncbi.nlm.nih.gov/10954463/
140.Kim, S.H., et al. Uterine cervical carcinoma: comparison of CT and MR findings. Radiology, 1990. 175: 45.
https://pubmed.ncbi.nlm.nih.gov/2315503/
141.Kim, S.H., et al. Uterine cervical carcinoma: evaluation of pelvic lymph node metastasis with MR imaging. Radiology, 1994. 190: 807.
https://pubmed.ncbi.nlm.nih.gov/8115631/
142.Oyen, R.H., et al. Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology, 1994. 190: 315.
https://pubmed.ncbi.nlm.nih.gov/8284375/
143.Barentsz, J.O., et al. MR imaging of the male pelvis. Eur Radiol, 1999. 9: 1722.
https://pubmed.ncbi.nlm.nih.gov/10602944/
144.Dorfman, R.E., et al. Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology, 1991. 180: 319.
https://pubmed.ncbi.nlm.nih.gov/2068292/
145.Lonati, C., et al. Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology - Young Academic Urologists. Urol Oncol, 2022. 40: 195.e27.
https://pubmed.ncbi.nlm.nih.gov/35236621/
146.Vind-Kezunovic, S., et al. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Results from a High-volume Centre Including Long-term Follow-up. Eur Urol Focus, 2019. 5: 90.
https://pubmed.ncbi.nlm.nih.gov/28753817/
147.Mertens, L.S., et al. Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy. Eur Urol, 2023. 83: 95.
https://pubmed.ncbi.nlm.nih.gov/36202686/
148.Ha, H.K., et al. Diagnostic Accuracy of F-18 FDG PET/CT for Preoperative Lymph Node Staging in Newly Diagnosed Bladder Cancer Patients: A Systematic Review and Meta-Analysis. Oncology, 2018. 95: 31.
https://pubmed.ncbi.nlm.nih.gov/29847834/
149.Einerhand, S.M.H., et al. 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer. Curr Opin Urol, 2020. 30: 654.
https://pubmed.ncbi.nlm.nih.gov/32701719/
150.Voskuilen, C.S., et al. Staging (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Changes Treatment Recommendation in Invasive Bladder Cancer. Eur Urol Oncol, 2022. 5: 366.
https://pubmed.ncbi.nlm.nih.gov/33583752/
151.Marandino, L., et al. [18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. Urol Oncol, 2021. 39: 235.e15.
https://pubmed.ncbi.nlm.nih.gov/33071107/
152.Girvin, F., et al. Pulmonary nodules: detection, assessment, and CAD. AJR Am J Roentgenol, 2008. 191: 1057.
https://pubmed.ncbi.nlm.nih.gov/18806142/
153.Heidenreich, A., et al. Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urol Int, 2010. 85: 1.
https://pubmed.ncbi.nlm.nih.gov/20693823/
154.Furrer, M.A., et al. Routine Preoperative Bone Scintigraphy Has Limited Impact on the Management of Patients with Invasive Bladder Cancer. Eur Urol Focus, 2021. 7: 1052.
https://pubmed.ncbi.nlm.nih.gov/33060038/
155.Papageorgiou, I., et al. Whole-body MRI: a powerful alternative to bone scan for bone marrow staging without radiation and gadolinium enhancer. Clin Transl Oncol, 2020. 22: 1321.
https://pubmed.ncbi.nlm.nih.gov/31858434/
156.Yoshida, S., et al. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys, 2012. 83: e21.
https://pubmed.ncbi.nlm.nih.gov/22414281/
157.Bandini, M., et al. The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. Eur Urol Oncol, 2021. 4: 829.
https://pubmed.ncbi.nlm.nih.gov/32605888/
158.Schrier, B.P., et al. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur Urol, 2006. 49: 698.
https://pubmed.ncbi.nlm.nih.gov/16464531/
159.Hafeez, S., et al. Assessing Bladder Radiotherapy Response With Quantitative Diffusion-Weighted Magnetic Resonance Imaging Analysis. Clin Oncol (R Coll Radiol), 2022. 34: 630.
https://pubmed.ncbi.nlm.nih.gov/35534398/
160.Pecoraro, M., et al. Vesical Imaging-Reporting and Data System (VI-RADS) for assessment of response to systemic therapy for bladder cancer: preliminary report. Abdom Radiol (NY), 2022. 47: 763.
https://pubmed.ncbi.nlm.nih.gov/34919160/
161.Kozikowski, M., et al. Role of Radiomics in the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus, 2022. 8: 728.
https://pubmed.ncbi.nlm.nih.gov/34099417/
162.Civelek, A.C., et al. Clinical value of (18)FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. Urol Oncol, 2021. 39: 787.e17.
https://pubmed.ncbi.nlm.nih.gov/34140245/
163.Rietbergen, D.D.D., et al. Evaluation of the Hybrid Tracer Indocyanine Green- 99m Tc-Nanocolloid for Sentinel Node Biopsy in Bladder Cancer-A Prospective Pilot Study. Clin Nucl Med, 2022. 47: 774.
https://pubmed.ncbi.nlm.nih.gov/35713891/
164.Game, X., et al. Radical cystectomy in patients older than 75 years: assessment of morbidity and mortality. Eur Urol, 2001. 39: 525.
https://pubmed.ncbi.nlm.nih.gov/11464032/
165.Clark, P.E., et al. Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer, 2005. 104: 36.
https://pubmed.ncbi.nlm.nih.gov/15912515/
166.May, M., et al. Results from three municipal hospitals regarding radical cystectomy on elderly patients. Int Braz J Urol, 2007. 33: 764.
https://pubmed.ncbi.nlm.nih.gov/18199344/
167.Ethun, C.G., et al. Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology. CA Cancer J Clin, 2017. 67: 362.
https://pubmed.ncbi.nlm.nih.gov/28731537/
168.Miller, D.C., et al. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol, 2003. 169: 105.
https://pubmed.ncbi.nlm.nih.gov/12478114/
169.Haden, T.D., et al. Comparative Perioperative Outcomes in Septuagenarians and Octogenarians Undergoing Radical Cystectomy for Bladder Cancer-Do Outcomes Differ? Eur Urol Focus, 2018.
4: 895.
https://pubmed.ncbi.nlm.nih.gov/28865996/
170.Brown, A.S., et al. National Institutes of Health Consensus Development Conference Statement: Geriatric Assessment Methods for Clinical Decision-making. J A Geriatr Soc, 1988. 36: 342.
https://pubmed.ncbi.nlm.nih.gov/3280648/
171.Mayr, R., et al. Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer. J Cachexia Sarcopenia Muscle, 2018. 9: 505.
https://pubmed.ncbi.nlm.nih.gov/29479839/
172.Lyon, T.D., et al. Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer, 2019. 17: 216.
https://pubmed.ncbi.nlm.nih.gov/31060857/
173.Lawrentschuk, N., et al. Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol, 2010. 57: 983.
https://pubmed.ncbi.nlm.nih.gov/20227172/
174.Donahue, T.F., et al. Risk factors for the development of parastomal hernia after radical cystectomy. J Urol, 2014. 191: 1708.
https://pubmed.ncbi.nlm.nih.gov/24384155/
175.Djaladat, H., et al. The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer. BJU Int, 2014. 113: 887.
https://pubmed.ncbi.nlm.nih.gov/23906037/
176.Garg, T., et al. Preoperative serum albumin is associated with mortality and complications after radical cystectomy. BJU Int, 2014. 113: 918.
https://pubmed.ncbi.nlm.nih.gov/24053616/
177.Rochon, P.A., et al. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. A prospective comparison of three comorbidity indices. Med Care, 1996. 34: 1093.
https://pubmed.ncbi.nlm.nih.gov/8911426/
178.Williams, S.B., et al. Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. Eur Urol Oncol, 2018. 1: 91.
https://pubmed.ncbi.nlm.nih.gov/30345422/
179.Zietman, A.L., et al. Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy. Ann Med, 2000. 32: 34.
https://pubmed.ncbi.nlm.nih.gov/10711576/
180.Lughezzani, G., et al. A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. Cancer, 2011. 117: 103.
https://pubmed.ncbi.nlm.nih.gov/20803606/
181.Froehner, M., et al. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol, 2009. 56: 443.
https://pubmed.ncbi.nlm.nih.gov/19481861/
182.Korc-Grodzicki, B., et al. Prevention of post-operative delirium in older patients with cancer undergoing surgery. J Geriatr Oncol, 2015. 6: 60.
https://pubmed.ncbi.nlm.nih.gov/25454768/
183.Soubeyran, P., et al. Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. PLoS One, 2014. 9: e115060.
https://pubmed.ncbi.nlm.nih.gov/25503576/
184.Rockwood, K., et al. A global clinical measure of fitness and frailty in elderly people. Cmaj, 2005. 173: 489.
https://pubmed.ncbi.nlm.nih.gov/16129869/
185.de Groot, V., et al. How to measure comorbidity. a critical review of available methods. J Clin Epidemiol, 2003. 56: 221.
https://pubmed.ncbi.nlm.nih.gov/12725876/
186.Linn, B.S., et al. Cumulative illness rating scale. J Am Geriatr Soc, 1968. 16: 622.
https://pubmed.ncbi.nlm.nih.gov/5646906/
187.Charlson, M.E., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis, 1987. 40: 373.
https://pubmed.ncbi.nlm.nih.gov/3558716/
188.Litwin, M.S., et al. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer, 2007. 109: 1777.
https://pubmed.ncbi.nlm.nih.gov/17354226/
189.Paleri, V., et al. Applicability of the adult comorbidity evaluation - 27 and the Charlson indexes to assess comorbidity by notes extraction in a cohort of United Kingdom patients with head and neck cancer: a retrospective study. J Laryngol Otol, 2002. 116: 200.
https://pubmed.ncbi.nlm.nih.gov/11893262/
190.Greenfield, S., et al. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care, 1993. 31: 141.
https://pubmed.ncbi.nlm.nih.gov/8433577/
191.Kaplan, M.H., et al. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis, 1974. 27: 387.
https://pubmed.ncbi.nlm.nih.gov/4436428/
192.Farhat, J.S., et al. Are the frail destined to fail? Frailty index as predictor of surgical morbidity and mortality in the elderly. J Trauma Acute Care Surg, 2012. 72: 1526.
https://pubmed.ncbi.nlm.nih.gov/22695416/
193.Mayr, R., et al. Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder. BJU Int, 2012. 110: E222.
https://pubmed.ncbi.nlm.nih.gov/22314129/
194.Morgan, T.M., et al. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol, 2011. 186: 829.
https://pubmed.ncbi.nlm.nih.gov/21788035/
195.Abdollah, F., et al. Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study. Ann Surg Oncol, 2012. 19: 309.
https://pubmed.ncbi.nlm.nih.gov/21701925/
196.Koppie, T.M., et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer, 2008. 112: 2384.
https://pubmed.ncbi.nlm.nih.gov/18404699/
197.Bolenz, C., et al. Management of elderly patients with urothelial carcinoma of the bladder: guideline concordance and predictors of overall survival. BJU Int, 2010. 106: 1324.
https://pubmed.ncbi.nlm.nih.gov/20500510/
198.Yoo, S., et al. Does radical cystectomy improve overall survival in octogenarians with muscle-invasive bladder cancer? Korean J Urol, 2011. 52: 446.
https://pubmed.ncbi.nlm.nih.gov/21860763/
199.Mayr, R., et al. Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur Urol, 2012. 62: 662.
https://pubmed.ncbi.nlm.nih.gov/22534059/
200.Hall, W.H., et al. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer, 2004. 4: 94.
https://pubmed.ncbi.nlm.nih.gov/15610554/
201.Extermann, M., et al. Comorbidity and functional status are independent in older cancer patients.
J Clin Oncol, 1998. 16: 1582.
https://pubmed.ncbi.nlm.nih.gov/9552069/
202.Blagden, S.P., et al. Performance status score: do patients and their oncologists agree? Br J Cancer, 2003. 89: 1022.
https://pubmed.ncbi.nlm.nih.gov/12966419/
203.Logothetis, C.J., et al. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol, 1995. 13: 2272.
https://pubmed.ncbi.nlm.nih.gov/7666085/
204.von der Maase, H., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 2000. 18: 3068.
https://pubmed.ncbi.nlm.nih.gov/11001674/
205.Niegisch, G., et al. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99). Eur Urol, 2011. 60: 1087.
https://pubmed.ncbi.nlm.nih.gov/21839579/
206.Cohen, H.J., et al. A controlled trial of inpatient and outpatient geriatric evaluation and management. N Engl J Med, 2002. 346: 905.
https://pubmed.ncbi.nlm.nih.gov/11907291/
207.Balducci, L., et al. General guidelines for the management of older patients with cancer. Oncology (Williston Park), 2000. 14: 221.
https://pubmed.ncbi.nlm.nih.gov/11195414/
208.Castagneto, B., et al. Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment. Oncology, 2004. 67: 27.
https://pubmed.ncbi.nlm.nih.gov/15459492/
209.Dutta, R., et al. Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. Urol Oncol, 2016. 34: 531.e1.
https://pubmed.ncbi.nlm.nih.gov/27427223/
210.Mathieu, R., et al. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol, 2016. 13: 471.
https://pubmed.ncbi.nlm.nih.gov/27431340/
211.Kimura, S., et al. Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis. J Urol, 2019. 201: 46.
https://pubmed.ncbi.nlm.nih.gov/30077559/
212.Svatek, R.S., et al. Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. Urology, 2014. 84: 1147.
https://pubmed.ncbi.nlm.nih.gov/25174656/
213.Donat, S.M., et al. Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance. J Urol, 2001. 165: 1117.
https://pubmed.ncbi.nlm.nih.gov/11257650/
214.Paner, G.P., et al. Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances. Adv Anat Pathol, 2017. 24: 113.
https://pubmed.ncbi.nlm.nih.gov/28398951/
215.Moschini, M., et al. Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. Bladder Cancer, 2017. 3: 161.
https://pubmed.ncbi.nlm.nih.gov/28824943/
216.Wu, S., et al. Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor in Bladder Cancer and Metastatic or Unresectable Urothelial Carcinoma Patients: a Pooled Analysis of Comparative Studies. Cell Physiol Biochem, 2018. 46: 1352.
https://pubmed.ncbi.nlm.nih.gov/29689562/
217.Ojerholm, E., et al. Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer, 2017. 123: 794.
https://pubmed.ncbi.nlm.nih.gov/27787873/
218.Ku, J.H., et al. Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis. BMC Cancer, 2015. 15: 447.
https://pubmed.ncbi.nlm.nih.gov/26027955/
219.Lee, D., et al. Lymph node density vs. the American Joint Committee on Cancer TNM nodal staging system in node-positive bladder cancer in patients undergoing extended or super-extended pelvic lymphadenectomy. Urol Oncol, 2017. 35: 151.e1.
https://pubmed.ncbi.nlm.nih.gov/28139370/
220.Oszwald, A., et al. Pathological reporting of cystectomy lymph nodes: a retrospective analysis of experience in Paris. World J Urol, 2021. 39: 4029.
https://pubmed.ncbi.nlm.nih.gov/33743060/
221.Jensen, J.B., et al. Evaluation of different lymph node (LN) variables as prognostic markers in patients undergoing radical cystectomy and extended LN dissection to the level of the inferior mesenteric artery. BJU Int, 2012. 109: 388.
https://pubmed.ncbi.nlm.nih.gov/21851538/
222.Bruins, H.M., et al. Critical evaluation of the American Joint Committee on Cancer TNM nodal staging system in patients with lymph node-positive disease after radical cystectomy. Eur Urol, 2012. 62: 671.
https://pubmed.ncbi.nlm.nih.gov/22575915/
223.Robertson, A.G., et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 2017. 171: 540.
https://pubmed.ncbi.nlm.nih.gov/28988769/
224.Choi, W., et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol, 2014. 11: 400.
https://pubmed.ncbi.nlm.nih.gov/24960601/
225.Kamoun, A., et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol, 2020. 77: 420.
https://pubmed.ncbi.nlm.nih.gov/31563503/
226.Abudurexiti, M., et al. Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer. Front Oncol, 2019. 9: 856.
https://pubmed.ncbi.nlm.nih.gov/31552180/
227.Morera, D.S., et al. Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA. J Urol, 2020. 203: 62.
https://pubmed.ncbi.nlm.nih.gov/31112107/
228.Compérat, E., et al. The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Adv Anat Pathol, 2021. 28: 196.
https://pubmed.ncbi.nlm.nih.gov/34128484/
229.Pietzak, E.J., et al. Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. Eur Urol, 2019. 75: 231.
https://pubmed.ncbi.nlm.nih.gov/30290956/
230.Motterle, G., et al. Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol Focus, 2020. 6: 642.
https://pubmed.ncbi.nlm.nih.gov/31708469/
231.Shariat, S.F., et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol, 2010. 183: 1744.
https://pubmed.ncbi.nlm.nih.gov/20299037/
232.Plimack, E.R., et al. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol, 2015. 68: 959.
https://pubmed.ncbi.nlm.nih.gov/26238431/
233.Van Allen, E.M., et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov, 2014. 4: 1140.
https://pubmed.ncbi.nlm.nih.gov/25096233/
234.Loriot, Y., et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med, 2019. 381: 338.
https://pubmed.ncbi.nlm.nih.gov/31340094/
235.Pal, S.K., et al. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. Cancer Discov, 2018. 8: 812.
https://pubmed.ncbi.nlm.nih.gov/29848605/
236.Rosenberg, J.E., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, 2016. 387: 1909.
https://pubmed.ncbi.nlm.nih.gov/26952546/
237.EMA restricts use of Keytruda and Tecentriq in bladder cancer. 2018. 2021.
https://www.ema.europa.eu/en/news/ema-restricts-use-keytruda-tecentriq-bladder-cancer#
238.Kandoth, C., et al. Mutational landscape and significance across 12 major cancer types. Nature, 2013. 502: 333.
https://pubmed.ncbi.nlm.nih.gov/24132290/
239.Sharma, P., et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol, 2016. 17: 1590.
https://pubmed.ncbi.nlm.nih.gov/27733243/
240.Powles, T., et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med, 2019. 25: 1706.
https://pubmed.ncbi.nlm.nih.gov/31686036/
241.Necchi, A., et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol, 2018. 36: 3353.
https://pubmed.ncbi.nlm.nih.gov/30343614/
242.Mariathasan, S., et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature, 2018. 554: 544.
https://pubmed.ncbi.nlm.nih.gov/29443960/
243.Wang, L., et al. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nature Com, 2018. 9: 3503.
https://pubmed.ncbi.nlm.nih.gov/30158554/
244.Powles, T., et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature, 2021.
595: 432.
https://pubmed.ncbi.nlm.nih.gov/34135506/
245.A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011). ClinicalTrials NCT04660344. Access date December 2022.
https://clinicaltrials.gov/ct2/show/NCT04660344
246.Stein, J.P., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol, 2001. 19: 666.
https://pubmed.ncbi.nlm.nih.gov/11157016/
247.Stein, J.P., et al. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol, 2006. 24: 296.
https://pubmed.ncbi.nlm.nih.gov/16518661/
248.Dalbagni, G., et al. Cystectomy for bladder cancer: a contemporary series. J Urol, 2001. 165: 1111.
https://pubmed.ncbi.nlm.nih.gov/11257649/
249.Bassi, P., et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol, 1999. 161: 1494.
https://pubmed.ncbi.nlm.nih.gov/10210380/
250.Ghoneim, M.A., et al. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol, 1997. 158: 393.
https://pubmed.ncbi.nlm.nih.gov/9224310/
251.David, K.A., et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol, 2007. 178: 451.
https://pubmed.ncbi.nlm.nih.gov/17561135/
252.Porter, M.P., et al. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol, 2011. 29: 252.
https://pubmed.ncbi.nlm.nih.gov/19450992/
253.Ravi, P., et al. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. BJU Int, 2021. 128: 607.
https://pubmed.ncbi.nlm.nih.gov/33909949/
254.Sanchez-Ortiz, R.F., et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol, 2003.
169: 110.
https://pubmed.ncbi.nlm.nih.gov/12478115/
255.Stein, J.P. Contemporary concepts of radical cystectomy and the treatment of bladder cancer.
J Urol, 2003. 169: 116.
https://pubmed.ncbi.nlm.nih.gov/12478116/
256.Boeri, L., et al. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes. Eur Urol Oncol, 2019. 2: 390.
https://pubmed.ncbi.nlm.nih.gov/31277775/
257.Pfail, J.L., et al. Survival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer Database. Bladder Cancer, 2020. 6: 265.
https://content.iospress.com/articles/bladder-cancer/blc200303
258.Pfister, C., et al. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Eur Urol, 2021. 79: 214.
https://pubmed.ncbi.nlm.nih.gov/32868138/
259.Grossman, H.B., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med, 2003. 349: 859.
https://pubmed.ncbi.nlm.nih.gov/12944571/
260.Sherif, A., et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol, 2004. 45: 297.
https://pubmed.ncbi.nlm.nih.gov/15036674/
261.Kimura, S., et al. Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer, 2020. 18: 78.
https://pubmed.ncbi.nlm.nih.gov/31889669/
262.D’Andrea, D., et al. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urol Oncol, 2020. 38: 639.e1.
https://pubmed.ncbi.nlm.nih.gov/32057595/
263.Griffiths, G., et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol, 2011. 29: 2171.
https://pubmed.ncbi.nlm.nih.gov/21502557/
264.Sherif, A., et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2. Scand J Urol Nephrol, 2002. 36: 419.
https://pubmed.ncbi.nlm.nih.gov/12623505/
265.Sengelov, L., et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol, 2002. 41: 447.
https://pubmed.ncbi.nlm.nih.gov/12442921/
266.Orsatti, M., et al. Alternating chemo-radiotherapy in bladder cancer: a conservative approach. Int
J Radiat Oncol Biol Phys, 1995. 33: 173.
https://pubmed.ncbi.nlm.nih.gov/7642415/
267.Shipley, W.U., et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol, 1998. 16: 3576.
https://pubmed.ncbi.nlm.nih.gov/9817278/
268.Abol-Enein H., et al. Neo-adjuvant chemotherapy in the treatment of invasive transitional bladder cancer. A controlled prospective randomized study. Br J Urol 1997. 79: 174. [No abstract available].
269.Collaboration, A.B.C.M.-a. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet, 2003. 361: 1927.
https://pubmed.ncbi.nlm.nih.gov/12801735/
270.Winquist, E., et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol, 2004. 171: 561.
https://pubmed.ncbi.nlm.nih.gov/14713760/
271.Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol, 2005. 48: 202.
https://pubmed.ncbi.nlm.nih.gov/15939524/
272.Wallace, D.M., et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol, 1991. 67: 608.
https://pubmed.ncbi.nlm.nih.gov/2070206/
273.Martinez-Pineiro, J.A., et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol, 1995. 153: 964.
https://pubmed.ncbi.nlm.nih.gov/7853584/
274.Rintala, E., et al. Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I. Scand J Urol Nephrol, 1993. 27: 355.
https://pubmed.ncbi.nlm.nih.gov/8290916/
275.Malmstrom, P.U., et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol, 1996. 155: 1903.
https://pubmed.ncbi.nlm.nih.gov/8618283/
276.Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet, 1999. 354: 533.
https://pubmed.ncbi.nlm.nih.gov/10470696/
277.Yin, M., et al. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist, 2016. 21: 708.
https://pubmed.ncbi.nlm.nih.gov/27053504/
278.Galsky, M.D., et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer, 2015. 121: 2586.
https://pubmed.ncbi.nlm.nih.gov/25872978/
279.Yuh, B.E., et al. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J Urol, 2013. 189: 1682.
https://pubmed.ncbi.nlm.nih.gov/23123547/
280.Lee, F.C., et al. Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Adv Urol, 2013. 2013: 317190.
https://pubmed.ncbi.nlm.nih.gov/24382958/
281.Dash, A., et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer, 2008. 113: 2471.
https://pubmed.ncbi.nlm.nih.gov/18823036/
282.Choueiri, T.K., et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol, 2014. 32: 1889.
https://pubmed.ncbi.nlm.nih.gov/24821883/
283.Plimack, E.R., et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol, 2014.
32: 1895.
https://pubmed.ncbi.nlm.nih.gov/24821881/
284.Peyton, C.C., et al. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Oncol, 2018. 4: 1535.
https://pubmed.ncbi.nlm.nih.gov/30178038/
285.Pfister, C., et al. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. J Clin Oncol, 2022. 40: 2013.
https://pubmed.ncbi.nlm.nih.gov/35254888/
286.Anari, F., et al. Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol, 2018. 1: 54.
https://pubmed.ncbi.nlm.nih.gov/30420974/
287.Iyer, G., et al. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol, 2018. 36: 1949.
https://pubmed.ncbi.nlm.nih.gov/29742009/
288.Osterman, C.K., et al. Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer. Oncologist, 2019. 24: 688.
https://pubmed.ncbi.nlm.nih.gov/30728277/
289.Hussain, S.A., et al. Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. Lancet Oncol, 2022. 23: 650.
https://pubmed.ncbi.nlm.nih.gov/35421369/
290.D’Andrea, D., et al. The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy. Eur Urol Open Sci, 2022. 41: 74.
https://pubmed.ncbi.nlm.nih.gov/35813257/
291.Vetterlein, M.W., et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer, 2017. 123: 4346.
https://pubmed.ncbi.nlm.nih.gov/28743155/
292.Chakiryan, N.H., et al. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. J Urol, 2021. 206: 924.
https://pubmed.ncbi.nlm.nih.gov/34032503/
293.Letocha, H., et al. Positron emission tomography with L-methyl-11C-methionine in the monitoring of therapy response in muscle-invasive transitional cell carcinoma of the urinary bladder. Br J Urol, 1994. 74: 767.
https://pubmed.ncbi.nlm.nih.gov/7827849/
294.Nishimura, K., et al. The effects of neoadjuvant chemotherapy and chemo-radiation therapy on MRI staging in invasive bladder cancer: comparative study based on the pathological examination of whole layer bladder wall. Int Urol Nephrol, 2009. 41: 869.
https://pubmed.ncbi.nlm.nih.gov/19396568/
295.Barentsz, J.O., et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology, 1998. 207: 791.
https://pubmed.ncbi.nlm.nih.gov/9609906/
296.Krajewski, K.M., et al. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer, 2012. 48: 1495.
https://pubmed.ncbi.nlm.nih.gov/22176867/
297.Rosenblatt, R., et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol, 2012. 61: 1229.
https://pubmed.ncbi.nlm.nih.gov/22189383/
298.Voskuilen, C.S., et al. Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. Am J Surg Pathol, 2019. 43: 1600.
https://pubmed.ncbi.nlm.nih.gov/31524642/
299.Sjödahl, G., et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol, 2022. 81: 523.
https://pubmed.ncbi.nlm.nih.gov/34782206/
300.Takata, R., et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res, 2005. 11: 2625.
https://pubmed.ncbi.nlm.nih.gov/15814643/
301.Takata, R., et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci, 2007. 98: 113.
https://pubmed.ncbi.nlm.nih.gov/17116130/
302.Miron, B., et al. Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol Oncol, 2020.
3: 544.
https://pubmed.ncbi.nlm.nih.gov/32165095/
303.Szabados, B., et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol, 2022. 82: 212.
https://pubmed.ncbi.nlm.nih.gov/35577646/
304.Rose, T.L., et al. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol, 2021. 39: 3140.
https://pubmed.ncbi.nlm.nih.gov/34428076/
305.Funt, S.A., et al. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. J Clin Oncol, 2022. 40: 1312.
https://pubmed.ncbi.nlm.nih.gov/35089812/
306.Zaghloul, M.S., et al. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial. JAMA Surg, 2018. 153: e174591.
https://pubmed.ncbi.nlm.nih.gov/29188298/
307.Iwata, T., et al. The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. Urol Oncol, 2019. 37: 659.
https://pubmed.ncbi.nlm.nih.gov/31255542/
308.Ballas, L., et al. Tolerance of Orthotopic Ileal Neobladders to Radiotherapy: A Multi-institutional Retrospective Study. Clin Genitourin Cancer, 2017. 15: 711.
https://pubmed.ncbi.nlm.nih.gov/28558986/
309.Slack, N.H., et al. Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder. J Surg Oncol, 1977. 9: 393.
https://pubmed.ncbi.nlm.nih.gov/330958/
310.Smith, J.A., Jr., et al. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study. J Urol, 1997. 157: 805.
https://pubmed.ncbi.nlm.nih.gov/9072571/
311.Ghoneim, M.A., et al. Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. J Urol, 1985. 134: 266.
https://pubmed.ncbi.nlm.nih.gov/3894693/
312.Anderstrom, C., et al. A prospective randomized study of preoperative irradiation with cystectomy or cystectomy alone for invasive bladder carcinoma. Eur Urol, 1983. 9: 142.
https://pubmed.ncbi.nlm.nih.gov/6861819/
313.Blackard, C.E., et al. Results of a clinical trial of surgery and radiation in stages II and 3 carcinoma of the bladder. J Urol, 1972. 108: 875.
https://pubmed.ncbi.nlm.nih.gov/5082739/
314.Vassantachart, A., et al. Feasibility and Outcomes of Orthotopic Ileal Neobladder Reconstruction Following Pelvic Irradiation. Urology, 2021. 148: 198.
https://pubmed.ncbi.nlm.nih.gov/32979377/
315.Huncharek, M., et al. Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis. Anticancer Res, 1998. 18: 1931.
https://pubmed.ncbi.nlm.nih.gov/9677446/
316.El-Monim, H.A., et al. A prospective randomized trial for postoperative vs. preoperative adjuvant radiotherapy for muscle-invasive bladder cancer. Urol Oncol, 2013. 31: 359.
https://pubmed.ncbi.nlm.nih.gov/21353794/
317.Lenis, A.T., et al. Urinary Diversion. JAMA, 2020. 324: 2222.
https://pubmed.ncbi.nlm.nih.gov/33258891/
318.Ornaghi, P.I., et al. Frailty impact on postoperative complications and early mortality rates in patients undergoing radical cystectomy for bladder cancer: a systematic review. Arab J Urol, 2020. 19: 9.
https://pubmed.ncbi.nlm.nih.gov/33763244/
319.Ornaghi, P.I., et al. The impact of preoperative nutritional status on post-surgical complication and mortality rates in patients undergoing radical cystectomy for bladder cancer: a systematic review of the literature. World J Urol, 2021. 39: 1045.
https://pubmed.ncbi.nlm.nih.gov/32519225/
320.Niu, S., et al. Preoperative Risk Factors Predicting Postoperative Complications in Radical Cystectomy for Bladder Cancer. Bladder Cancer, 2020. 6: 151.
https://content.iospress.com/articles/bladder-cancer/blc200290
321.Russell, B., et al. A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer Patients. Eur Urol Oncol, 2020. 3: 239.
https://pubmed.ncbi.nlm.nih.gov/31668714/
322.Fahmy, O., et al. Clinicopathological Features and Prognostic Value of Incidental Prostatic Adenocarcinoma in Radical Cystoprostatectomy Specimens: A Systematic Review and Meta-Analysis of 13,140 Patients. J Urol, 2017. 197: 385.
https://pubmed.ncbi.nlm.nih.gov/27569436/
323.Mottet, N., et al, EAU-EANM-ESTRO-ESUR-ISUP-SIOG Prostate Cancer Guidelines. In: EAU Guidelines presented at the 38th EAU Annual Congress Milan 2023. EAU Guidelines Office Arnhem, The Netherlands.
https://uroweb.org/guidelines/prostate-cancer
324.Hernandez, V., et al. Oncological and functional outcomes of sexual function-preserving cystectomy compared with standard radical cystectomy in men: A systematic review. Urol Oncol, 2017. 35: 539.e17.
https://pubmed.ncbi.nlm.nih.gov/28495555/
325.Voigt, M., et al. Influence of Simple and Radical Cystectomy on Sexual Function and Pelvic Organ Prolapse in Female Patients: A Scoping Review of the Literature. Sex Med Rev, 2019. 7: 408.
https://pubmed.ncbi.nlm.nih.gov/31029621/
326.Ali-El-Dein, B., et al. Preservation of the internal genital organs during radical cystectomy in selected women with bladder cancer: a report on 15 cases with long term follow-up. Eur J Surg Oncol, 2013. 39: 358.
https://pubmed.ncbi.nlm.nih.gov/23422323/
327.Bree, K.K., et al. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. J Urol, 2021. 206: 577.
https://pubmed.ncbi.nlm.nih.gov/33872050/
328.Temkin, S.M., et al. Ovarian Cancer Prevention in High-risk Women. Clin Obstet Gynecol, 2017. 60: 738.
https://pubmed.ncbi.nlm.nih.gov/28957949/
329.Veskimae, E., et al. Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. BJU Int, 2017. 120: 12.
https://pubmed.ncbi.nlm.nih.gov/28220653/
330.Patel, S.H., et al. Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage. Clin Genitourin Cancer, 2022. 20: 60.
https://pubmed.ncbi.nlm.nih.gov/34896022/
331.Bai, S., et al. The Feasibility and Safety of Reproductive Organ Preserving Radical Cystectomy for Elderly Female Patients With Muscle-Invasive Bladder Cancer: A Retrospective Propensity Score-matched Study. Urology, 2019. 125: 138.
https://pubmed.ncbi.nlm.nih.gov/30445122/
332.Simone, G., et al. Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy. Int J Urol, 2013. 20: 390.
https://pubmed.ncbi.nlm.nih.gov/22970939/
333.Jensen, J.B., et al. Extended versus limited lymph node dissection in radical cystectomy: impact on recurrence pattern and survival. Int J Urol, 2012. 19: 39.
https://pubmed.ncbi.nlm.nih.gov/22050425/
334.Zehnder, P., et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol, 2011. 186: 1261.
https://pubmed.ncbi.nlm.nih.gov/21849183/
335.Wallmeroth, A., et al. Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): An autopsy study on 367 patients. Urol Int, 1999. 62: 69.
https://pubmed.ncbi.nlm.nih.gov/10461106/
336.Davies, J.D., et al. Anatomic basis for lymph node counts as measure of lymph node dissection extent: a cadaveric study. Urology, 2013. 81: 358.
https://pubmed.ncbi.nlm.nih.gov/23374802/
337.Jensen, J.B., et al. Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery. BJU Int, 2010. 106: 199.
https://pubmed.ncbi.nlm.nih.gov/20002670/
338.Leissner, J., et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol, 2004. 171: 139.
https://pubmed.ncbi.nlm.nih.gov/14665862/
339.Dorin, R.P., et al. Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study. Eur Urol, 2011. 60: 946.
https://pubmed.ncbi.nlm.nih.gov/21802833/
340.Bruins, H.M., et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. Eur Urol, 2014. 66: 1065.
https://pubmed.ncbi.nlm.nih.gov/25074764/
341.Faraj, K., et al. Robotic vs. open cystectomy: How length-of-stay differences relate conditionally to age. Urol Oncol, 2019. 37: 354.e1.
https://pubmed.ncbi.nlm.nih.gov/30770298/
342.Rai, B.P., et al. Robotic versus open radical cystectomy for bladder cancer in adults. Cochrane Database Syst Rev, 2019. 4: CD011903.
https://pubmed.ncbi.nlm.nih.gov/31016718/
343.Wijburg, C.J., et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Bladder Cancer Patients: A Multicentre Comparative Effectiveness Study. Eur Urol, 2021. 79: 609.
https://pubmed.ncbi.nlm.nih.gov/33446375/
344.Goh, A.C., et al. A Population-based Study of Ureteroenteric Strictures After Open and Robot-assisted Radical Cystectomy. Urology, 2020. 135: 57.
https://pubmed.ncbi.nlm.nih.gov/31618656/
345.Magnusson, J., et al. Cumulative incidence of ureteroenteric strictures after radical cystectomy in a population-based Swedish cohort. Scand J Urol, 2021. 55: 361.
https://pubmed.ncbi.nlm.nih.gov/34313191/
346.Hosseini, A., et al. Ureteric stricture rates and management after robot-assisted radical cystectomy: a single-centre observational study. Scand J Urol, 2018. 52: 244.
https://pubmed.ncbi.nlm.nih.gov/30103644/
347.Amin, K.A., et al. Predictors of Benign Ureteroenteric Anastomotic Strictures After Radical Cystectomy and Urinary Diversion. Urology, 2020. 144: 225.
https://pubmed.ncbi.nlm.nih.gov/29964128/
348.Faraj, K.S., et al. Effect of intracorporeal urinary diversion on the incidence of benign ureteroenteric stricture after cystectomy. Int J Urol, 2021. 28: 593.
https://pubmed.ncbi.nlm.nih.gov/33594730/
349.Ahmadi, N., et al. Use of indocyanine green to minimise uretero-enteric strictures after robotic radical cystectomy. BJU Int, 2019. 124: 302.
https://pubmed.ncbi.nlm.nih.gov/30815976/
350.Reesink, D.J., et al. Evaluation of Ureteroenteric Anastomotic Strictures after the Introduction of Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Results from a Large Tertiary Referral Center. J Urol, 2021. 205: 1119.
https://pubmed.ncbi.nlm.nih.gov/33249976/
351.Faraj, K.S., et al. Robot Assisted Radical Cystectomy vs Open Radical Cystectomy: Over 10 years of the Mayo Clinic Experience. Urol Oncol, 2019. 37: 862.
https://pubmed.ncbi.nlm.nih.gov/31526651/
352.Wei, L., et al. Accurate Quantification of Residual Cancer Cells in Pelvic Washing Reveals Association with Cancer Recurrence Following Robot-Assisted Radical Cystectomy. J Urol, 2019. 201: 1105.
https://pubmed.ncbi.nlm.nih.gov/30730413/
353.Hussein, A.A., et al. Outcomes of Intracorporeal Urinary Diversion after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. J Urol, 2018. 199: 1302.
https://pubmed.ncbi.nlm.nih.gov/29275112/
354.Zhang, J.H., et al. Large Single Institution Comparison of Perioperative Outcomes and Complications of Open Radical Cystectomy, Intracorporeal Robot-Assisted Radical Cystectomy and Robotic Extracorporeal Approach. J Urol, 2020. 203: 512.
https://pubmed.ncbi.nlm.nih.gov/31580189/
355.Catto, J.W.F., et al. Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial. JAMA, 2022. 327: 2092.
https://pubmed.ncbi.nlm.nih.gov/35569079/
356.Yang, L.S., et al. A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer. Surg Oncol, 2016. 25: 281.
https://pubmed.ncbi.nlm.nih.gov/27566035/
357.Cerruto, M.A., et al. Health-Related Quality of Life after Radical Cystectomy for Bladder Cancer in Elderly Patients with Ileal Orthotopic Neobladder or Ileal Conduit: Results from a Multicentre Cross-Sectional Study Using Validated Questionnaires. Urol Int, 2018. 100: 346.
https://pubmed.ncbi.nlm.nih.gov/29514144/
358.Korkes, F., et al. Bricker ileal conduit vs. Cutaneous ureterostomy after radical cystectomy for bladder cancer: a systematic review. Int Braz J Urol, 2022. 48: 18.
https://pubmed.ncbi.nlm.nih.gov/33861058/
359.Deliveliotis, C., et al. Urinary diversion in high-risk elderly patients: modified cutaneous ureterostomy or ileal conduit? Urology, 2005. 66: 299.
https://pubmed.ncbi.nlm.nih.gov/16040096/
360.Rezaee, M.E., et al. Ileal Conduit Versus Continent Urinary Diversion in Radical Cystectomy: A Retrospective Cohort Study of 30-day Complications, Readmissions, and Mortality. Urology, 2022.
https://pubmed.ncbi.nlm.nih.gov/36007686/
361.Izquierdo, L., et al. Radical cystectomy and orthotopic bladder substitution: surgical tricks and management of complications. Minerva Urol Nefrol, 2013. 65: 225.
https://pubmed.ncbi.nlm.nih.gov/24091476/
362.Abol-Enein, H., et al. Functional results of orthotopic ileal neobladder with serous-lined extramural ureteral reimplantation: experience with 450 patients. J Urol, 2001. 165: 1427.
https://pubmed.ncbi.nlm.nih.gov/11342891/
363.Thoeny, H.C., et al. Is ileal orthotopic bladder substitution with an afferent tubular segment detrimental to the upper urinary tract in the long term? J Urol, 2002. 168: 2030.
https://pubmed.ncbi.nlm.nih.gov/12394702/
364.Yossepowitch, O., et al. Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. J Urol, 2003. 169: 177.
https://pubmed.ncbi.nlm.nih.gov/12478130/
365.Laukhtina, E., et al. Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis. Urol Oncol, 2021. 39: 806.
https://pubmed.ncbi.nlm.nih.gov/34266740/
366.Wiesner, C., et al. Continent cutaneous urinary diversion: long-term follow-up of more than 800 patients with ileocecal reservoirs. World J Urol, 2006. 24: 315.
https://pubmed.ncbi.nlm.nih.gov/16676186/
367.Check, D.K., et al. Decision Regret Related to Urinary Diversion Choice among Patients Treated with Cystectomy. J Urol, 2020. 203: 159.
https://pubmed.ncbi.nlm.nih.gov/31441673/
368.Roth, B., et al. Positive Pre-cystectomy Biopsies of the Prostatic Urethra or Bladder Neck Do Not Necessarily Preclude Orthotopic Bladder Substitution. J Urol, 2019. 201: 909.
https://pubmed.ncbi.nlm.nih.gov/30694935/
369.Stein, J.P., et al. Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. J Urol, 2007. 178: 756.
https://pubmed.ncbi.nlm.nih.gov/17631333/
370.Gakis, G., et al. [Benefits and risks of orthotopic neobladder reconstruction in female patients]. Aktuelle Urol, 2011. 42: 109.
https://pubmed.ncbi.nlm.nih.gov/21437834/
371.Lebret, T., et al. After cystectomy, is it justified to perform a bladder replacement for patients with lymph node positive bladder cancer? Eur Urol, 2002. 42: 344.
https://pubmed.ncbi.nlm.nih.gov/12361899/
372.Nieder, A.M., et al. Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring. Urology, 2004. 64: 950.
https://pubmed.ncbi.nlm.nih.gov/15533484/
373.Xing, W., et al. Comparison of Health-Related Quality of Life Between Ileal Conduit Diversion and Orthotopic Neobladder in Women: A Meta-Analysis. Front Oncol, 2022. 12: 862884.
https://pubmed.ncbi.nlm.nih.gov/35419290/
374.Gershman, B., et al. Comparative impact of continent and incontinent urinary diversion on long-term renal function after radical cystectomy in patients with preoperative chronic kidney disease 2 and chronic kidney disease 3a. Int J Urol, 2015. 22: 651.
https://pubmed.ncbi.nlm.nih.gov/25881721/
375.Williams, S.B., et al. Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. Eur Urol, 2020. 78: 719.
https://pubmed.ncbi.nlm.nih.gov/32624275/
376.Xu, W., et al. Postoperative Pain Management after Radical Cystectomy: Comparing Traditional versus Enhanced Recovery Protocol Pathway. J Urol, 2015. 194: 1209.
https://pubmed.ncbi.nlm.nih.gov/26021824/
377.Chiang, H.A., et al. Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol. Eur Urol Focus, 2020. 6: 74.
https://pubmed.ncbi.nlm.nih.gov/30228076/
378.Tikkinen , K.A.O., et al. EAU Guidelines Thromboprophylaxis in Urological Surgery. In: EAU Guidelines presented at the 32nd EAU Annual Congers, London 2017. Arnhem, The Netherlands.
https://uroweb.org/guidelines/archive/thromboprophylaxis
379.Bochner, B.H., et al. Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. Eur Urol, 2015. 67: 1042.
https://pubmed.ncbi.nlm.nih.gov/25496767/
380.Mossanen, M., et al. Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. BJU Int, 2019. 124: 40.
https://pubmed.ncbi.nlm.nih.gov/30499636/
381.Demaegd, L., et al. Comparison of postoperative complications of ileal conduits versus orthotopic neobladders. Transl Androl Urol, 2020. 9: 2541.
https://pubmed.ncbi.nlm.nih.gov/33457228/
382.Cicione, A., et al. Complications and quality of life of ileal conduit, orthotopic neobladder and ureterocutaneostomy: systematic review of reports using the Clavien-Dindo Classification. Minerva Urol Nefrol, 2020. 72: 408.
https://pubmed.ncbi.nlm.nih.gov/32734749/
383.Haas, M., et al. The comprehensive complication index is associated with a significant increase in complication severity between 30 and 90 days after radical cystectomy for bladder cancer. Eur
J Surg Oncol, 2021. 47: 1163.
https://pubmed.ncbi.nlm.nih.gov/33046281/
384.Furrer, M.A., et al. The Comprehensive Complication Index CCI: A proposed modification to optimize short-term complication reporting after cystectomy and urinary diversion. Urol Oncol, 2019. 37: 291.e9.
https://pubmed.ncbi.nlm.nih.gov/30638668/
385.Hu, M., et al. Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer. Cancer, 2014. 120: 1409.
https://pubmed.ncbi.nlm.nih.gov/24477968/
386.Parker, W.P., et al. Utilization and Outcomes of Radical Cystectomy for High-grade Non-muscle-invasive Bladder Cancer in Elderly Patients. Clin Genitourin Cancer, 2017. 7673: 30208-2.
https://pubmed.ncbi.nlm.nih.gov/28844793/
387.Diamant, E., et al. Effectiveness of Early Radical Cystectomy for High-Risk Non-Muscle Invasive Bladder Cancer. Cancers, 2022. 14: 3797.
https://pubmed.ncbi.nlm.nih.gov/doi:10.3390/cancers14153797/
388.Nielsen, M.E., et al. Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base. BJU Int, 2014. 114: 46.
https://pubmed.ncbi.nlm.nih.gov/24219110/
389.Sari Motlagh, R., et al. Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. Curr Opin Urol, 2020. 30: 701.
https://pubmed.ncbi.nlm.nih.gov/32732625/
390.Schulz, G.B., et al. Surgical High-risk Patients With ASA > 3 Undergoing Radical Cystectomy: Morbidity, Mortality, and Predictors for Major Complications in a High-volume Tertiary Center. Clin Genitourin Cancer, 2018. 16: e1141.
https://pubmed.ncbi.nlm.nih.gov/30174234/
391.Hossain, D., Use of Clavien-Dindo classification in urology part 1 – pelvic surgery. Urol News 2016. 20.
392.Shabsigh, A., et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol, 2009. 55: 164.
https://pubmed.ncbi.nlm.nih.gov/18675501/
393.Buchner, A., et al. Dramatic impact of blood transfusion on cancer-specific survival after radical cystectomy irrespective of tumor stage. Scand J Urol, 2017. 51: 130.
https://pubmed.ncbi.nlm.nih.gov/28332428/
394.Hammond, J., et al. Rates of venous thromboembolism among patients with major surgery for cancer. Ann Surg Oncol, 2011. 18: 3240.
https://pubmed.ncbi.nlm.nih.gov/21584837/
395.Antoni, S., et al. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol, 2017. 71: 96.
https://pubmed.ncbi.nlm.nih.gov/27370177/
396.Fahmy, O., et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol, 2018. 36: 43.
https://pubmed.ncbi.nlm.nih.gov/29102254/
397.Darwish, C., et al. Trends in Treatment Strategies and Comparison of Outcomes in Lymph Node Positive Bladder Cancer: An Analysis of the National Cancer Database. Urology, 2020. 146: 168.
https://pubmed.ncbi.nlm.nih.gov/32866509/
398.Bruins, H.M., et al. The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. Eur Urol Oncol, 2020. 3: 131.
https://pubmed.ncbi.nlm.nih.gov/31866215/
399.Richters, A., et al. Hospital volume is associated with postoperative mortality after radical cystectomy for treatment of bladder cancer. BJU Int, 2021. 128: 511.
https://pubmed.ncbi.nlm.nih.gov/33404154/
400.Llorente, C., et al. Effect of hospital volume on 90-day mortality after radical cystectomy for bladder cancer in Spain. World J Urol, 2020. 38: 1221.
https://pubmed.ncbi.nlm.nih.gov/31302754/
401.Maisch, P., et al. Outcomes of palliative cystectomy in patients with locally advanced pT4 bladder cancer. Urol Oncol, 2021. 39: 368.e11.
https://pubmed.ncbi.nlm.nih.gov/33431328/
402.Pieretti, A., et al. Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy.
J Urol, 2021. 206: 29.
https://pubmed.ncbi.nlm.nih.gov/33617327/
403.Ghahestani, S.M., et al. Palliative treatment of intractable hematuria in context of advanced bladder cancer: a systematic review. Urol J, 2009. 6: 149.
https://pubmed.ncbi.nlm.nih.gov/19711266/
404.Srinivasan, V., et al. A comparison of two radiotherapy regimens for the treatment of symptoms from advanced bladder cancer. Clin Oncol (R Coll Radiol), 1994. 6: 11.
https://pubmed.ncbi.nlm.nih.gov/7513538/
405.Herr, H.W. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol, 1987. 138: 1162.
https://pubmed.ncbi.nlm.nih.gov/3669160/
406.Herr, H.W. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol, 2001. 19: 89.
https://pubmed.ncbi.nlm.nih.gov/11134199/
407.Holmäng, S., et al. Long-term followup of all patients with muscle invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region. J Urol, 1997. 158: 389.
https://pubmed.ncbi.nlm.nih.gov/9224309/
408.Solsona, E., et al. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol, 2010. 184: 475.
https://pubmed.ncbi.nlm.nih.gov/20620402/
409.Choudhury, A., et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol, 2021. 22: 246.
https://pubmed.ncbi.nlm.nih.gov/33539743/
410.Korpics, M., et al. Maximizing survival in patients with muscle-invasive bladder cancer undergoing curative bladder-preserving radiotherapy: the impact of radiotherapy dose escalation. J Radiat Oncol, 2017. 6: 387.
https://link.springer.com/article/10.1007/s13566-017-0319-2
411.Hafeez, S., et al. Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment. Int J Radiat Oncol Biol Phys, 2017. 98: 115.
https://pubmed.ncbi.nlm.nih.gov/28586948/
412.Milosevic, M., et al. Radiotherapy for bladder cancer. Urology, 2007. 69: 80.
https://pubmed.ncbi.nlm.nih.gov/17280910/
413.Sondergaard, J., et al. A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer. Acta Oncol, 2014. 53: 1321.
https://pubmed.ncbi.nlm.nih.gov/24980045/
414.Tonoli, S., et al. Radical radiotherapy for bladder cancer: retrospective analysis of a series of 459 patients treated in an Italian institution. Clin Oncol (R Coll Radiol), 2006. 18: 52.
https://pubmed.ncbi.nlm.nih.gov/16477920/
415.Shelley, M.D., et al. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev, 2002: CD002079.
https://pubmed.ncbi.nlm.nih.gov/11869621/
416.Booth, C.M., et al. Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study. Clin Oncol (R Coll Radiol), 2014. 26: 506.
https://pubmed.ncbi.nlm.nih.gov/24954284/
417.Korpics, M.C., et al. Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy. Cancer, 2017. 123: 3524.
https://pubmed.ncbi.nlm.nih.gov/28581675/
418.Sternberg, C.N., et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer, 2003. 97: 1644.
https://pubmed.ncbi.nlm.nih.gov/12655521/
419.Kachnic, L.A., et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol, 1997. 15: 1022.
https://pubmed.ncbi.nlm.nih.gov/9060542/
420.Als, A.B., et al. Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies. Eur Urol, 2007. 52: 478.
https://pubmed.ncbi.nlm.nih.gov/17383078/
421.Moran, G.W., et al. Systematic Review and Meta-Analysis on the Efficacy of Chemotherapy with Transurethral Resection of Bladder Tumors as Definitive Therapy for Muscle Invasive Bladder Cancer. Bladder Cancer, 2017. 3: 245.
https://pubmed.ncbi.nlm.nih.gov/29152549/
422.Audenet, F., et al. Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data. J Urol, 2018.
200: 996.
https://pubmed.ncbi.nlm.nih.gov/29879397/
423.Ploussard, G., et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol, 2014. 66: 120.
https://pubmed.ncbi.nlm.nih.gov/24613684/
424.James, N.D., et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. New Engl J Med, 2012. 366: 1477.
https://pubmed.ncbi.nlm.nih.gov/22512481/
425.Efstathiou, J.A., et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol, 2012. 61: 705.
https://pubmed.ncbi.nlm.nih.gov/22101114/
426.Merten, R., et al. Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). Oncologist, 2019. 24: e1341.
https://pubmed.ncbi.nlm.nih.gov/31292267/
427.Giacalone, N.J., et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol, 2017. 71: 952.
https://pubmed.ncbi.nlm.nih.gov/28081860/
428.Mak, R.H., et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol, 2014. 32: 3801.
https://pubmed.ncbi.nlm.nih.gov/25366678/
429.Suer, E., et al. Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy. World J Urol, 2016. 34: 847.
https://pubmed.ncbi.nlm.nih.gov/26462931/
430.Amestoy, F., et al. Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer. Crit Rev Oncol Hematol, 2019. 142: 76.
https://pubmed.ncbi.nlm.nih.gov/31377435/
431.Hoskin, P.J., et al. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
J Clin Oncol, 2010. 28: 4912.
https://pubmed.ncbi.nlm.nih.gov/20956620/
432.Coen, J.J., et al. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol, 2019. 37: 44.
https://pubmed.ncbi.nlm.nih.gov/30433852/
433.Kulkarni, G.S., et al. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol, 2017.
35: 2299.
https://pubmed.ncbi.nlm.nih.gov/28410011/
434.Krasnow, R.E., et al. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol, 2017. 72: 54.
https://pubmed.ncbi.nlm.nih.gov/28040351/
435.Eswara, J.R., et al. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol, 2012. 187: 463.
https://pubmed.ncbi.nlm.nih.gov/22177159/
436.Mitin, T., et al. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. Int
J Radiat Oncol Biol Phys, 2016. 94: 67.
https://pubmed.ncbi.nlm.nih.gov/26700703/
437.Sanchez, A., et al. Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer. J Urol, 2018. 199: 407.
https://pubmed.ncbi.nlm.nih.gov/28870862/
438.Ritch, C.R., et al. Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer. BJU Int, 2018. 121: 745.
https://pubmed.ncbi.nlm.nih.gov/29281848/
439.Cahn, D.B., et al. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. Cancer, 2017.
123: 4337.
https://pubmed.ncbi.nlm.nih.gov/28743162/
440.Efstathiou, J.A., et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol, 2009. 27: 4055.
https://pubmed.ncbi.nlm.nih.gov/19636019/
441.Huddart, R.A., et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol, 2020. 77: 260.
https://pubmed.ncbi.nlm.nih.gov/31843338/
442.Mak, K.S., et al. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. Int
J Radiat Oncol Biol Phys, 2016. 96: 1028.
https://pubmed.ncbi.nlm.nih.gov/27727064/
443.Sherry, A.D., et al. Intensity-modulated radiotherapy is superior to three-dimensional conformal radiotherapy in the trimodality management of muscle-invasive bladder cancer with daily cone beam computed tomography optimization. J Radiat Oncol, 2019. 8: 395.
https://pubmed.ncbi.nlm.nih.gov/33343830/
444.Quirt, J.S., et al. Patterns of Referral to Radiation Oncology among Patients with Bladder Cancer: a Population-based Study. Clin Oncol (R Coll Radiol), 2017. 29: 171.
https://pubmed.ncbi.nlm.nih.gov/27829531/
445.Cohen, S.M., et al. The role of perioperative chemotherapy in the treatment of urothelial cancer. Oncologist, 2006. 11: 630.
https://pubmed.ncbi.nlm.nih.gov/16794242/
446.Sylvester, R., et al. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol, 2000. 11: 851.
https://pubmed.ncbi.nlm.nih.gov/10997813/
447.Donat, S.M., et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol, 2009. 55: 177.
https://pubmed.ncbi.nlm.nih.gov/18640770/
448.Collaboration, A.B.C.A.M.-a. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol, 2005. 48: 189.
https://pubmed.ncbi.nlm.nih.gov/15939530/
449.Leow, J.J., et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol, 2014. 66: 42.
https://pubmed.ncbi.nlm.nih.gov/24018020/
450.Cognetti, F., et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol, 2012. 23: 695.
https://pubmed.ncbi.nlm.nih.gov/21859900/
451.Paz-Ares L.G., Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol (Meeting Abstracts), 2010. 28: 18_suppl LBA4518.
https://ascopubs.org/doi/abs/10.1200/jco.2010.28.18_suppl.lba4518
452.Stadler, W.M., et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol, 2011. 29: 3443.
https://pubmed.ncbi.nlm.nih.gov/21810677/
453.Lehmann, J., et al. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int, 2006. 97: 42.
https://pubmed.ncbi.nlm.nih.gov/16336326/
454.Ramani, V.A., et al. Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. Eur Urol, 2010. 57: 1058.
https://pubmed.ncbi.nlm.nih.gov/20022162/
455.Freiha, F., et al. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol, 1996.
155: 495.
https://pubmed.ncbi.nlm.nih.gov/8558644/
456.Stockle, M., et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol, 1995. 153: 47.
https://pubmed.ncbi.nlm.nih.gov/7966789/
457.Studer, U.E., et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol, 1994. 152: 81.
https://pubmed.ncbi.nlm.nih.gov/8201695/
458.Skinner, D.G., et al. Adjuvant chemotherapy following cystectomy benefits patients with deeply invasive bladder cancer. Semin Urol, 1990. 8: 279.
https://pubmed.ncbi.nlm.nih.gov/2284533/
459.Lehmann, J., et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol, 2005. 23: 4963.
https://pubmed.ncbi.nlm.nih.gov/15939920/
460.Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. Eur Urol, 2022. 81: 50.
https://pubmed.ncbi.nlm.nih.gov/34802798/
461.Svatek, R.S., et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res, 2010. 16: 4461.
https://pubmed.ncbi.nlm.nih.gov/20651056/
462.Sternberg, C.N., et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol, 2015. 16: 76.
https://pubmed.ncbi.nlm.nih.gov/25498218/
463.Galsky, M.D., et al. Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer.
J Clin Oncol, 2016. 34: 825.
https://pubmed.ncbi.nlm.nih.gov/26786930/
464.Berg, S., et al. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Cancer, 2019. 125: 1449.
https://pubmed.ncbi.nlm.nih.gov/30620387/
465.Bajorin, D.F., et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
N Engl J Med, 2021. 384: 2102.
https://pubmed.ncbi.nlm.nih.gov/34077643/
466.Bellmunt, J., et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol, 2021. 22: 525.
https://pubmed.ncbi.nlm.nih.gov/33721560/
467.FDA approves nivolumab for adjuvant treatment of urothelial carcinoma. U.S. Food & Drug Adminstration. Access date December 2022.
468.Hussain, S.A., et al. A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett, 2012. 3: 855.
https://pubmed.ncbi.nlm.nih.gov/22741006/
469.Galsky, M.D., et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol, 2011. 12: 211.
https://pubmed.ncbi.nlm.nih.gov/21376284/
470.Galsky, M.D., et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol, 2011. 29: 2432.
https://pubmed.ncbi.nlm.nih.gov/21555688/
471.Hussain, S.A., et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br
J Cancer, 2004. 91: 844.
https://pubmed.ncbi.nlm.nih.gov/15292922/
472.Morales-Barrera, R., et al. Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur J Cancer, 2012. 48: 1816.
https://pubmed.ncbi.nlm.nih.gov/22595043/
473.De Santis, M., et al. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol, 2009. 27: 5634.
https://pubmed.ncbi.nlm.nih.gov/19786668/
474.Bellmunt, J., et al. New therapeutic challenges in advanced bladder cancer. Semin Oncol, 2012.
39: 598.
https://pubmed.ncbi.nlm.nih.gov/23040256/
475.von der Maase, H., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol, 2005. 23: 4602.
https://pubmed.ncbi.nlm.nih.gov/16034041/
476.Sternberg, C.N., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol, 2001. 19: 2638.
https://pubmed.ncbi.nlm.nih.gov/11352955/
477.Sternberg, C.N., et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer, 2006. 42: 50.
https://pubmed.ncbi.nlm.nih.gov/16330205/
478.Bellmunt, J., et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol, 2012. 30: 1107.
https://pubmed.ncbi.nlm.nih.gov/22370319/
479.Rosenberg, J.E., et al. Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
J Clin Oncol, 2021. 39: 2486.
https://pubmed.ncbi.nlm.nih.gov/33989025/
480.Galsky, M.D., et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol, 2012. 23: 406.
https://pubmed.ncbi.nlm.nih.gov/21543626/
481.Bamias, A., et al. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Ann Oncol, 2018. 29: 361.
https://pubmed.ncbi.nlm.nih.gov/29077785/
482.Sternberg, C.N., et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer, 2001. 92: 2993.
https://pubmed.ncbi.nlm.nih.gov/11753976/
483.Meluch, A.A., et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol, 2001. 19: 3018.
https://pubmed.ncbi.nlm.nih.gov/11408496/
484.Calabro, F., et al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer, 2009. 115: 2652.
https://pubmed.ncbi.nlm.nih.gov/19396817/
485.De Santis, M., et al. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Ann Oncol, 2016. 27: 449.
https://pubmed.ncbi.nlm.nih.gov/26673352/
486.Galsky, M.D., et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, 2020. 395: 1547.
https://pubmed.ncbi.nlm.nih.gov/32416780/
487.Powles, T., et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol, 2021. 22: 931.
https://pubmed.ncbi.nlm.nih.gov/34051178/
488.Powles, T., et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol, 2020. 21: 1574.
https://pubmed.ncbi.nlm.nih.gov/32971005/
489.Balar, A.V., et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol, 2017. 18: 1483.
https://pubmed.ncbi.nlm.nih.gov/28967485/
490.Balar, A.V., et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, 2017. 389: 67.
https://pubmed.ncbi.nlm.nih.gov/27939400/
491.Galsky, M.D., et al. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. J Clin Oncol, 2020. 38: 1797.
https://pubmed.ncbi.nlm.nih.gov/32271672/
492.Powles, T., et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med, 2020. 383: 1218.
https://pubmed.ncbi.nlm.nih.gov/32945632/
493.Wong, R.L., et al. Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. Oncologist, 2021. 26: 1026.
https://pubmed.ncbi.nlm.nih.gov/34355457/
494.Oing, C., et al. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. J Urol, 2016. 195: 254.
https://pubmed.ncbi.nlm.nih.gov/26410730/
495.Raggi, D., et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol, 2016. 27: 49.
https://pubmed.ncbi.nlm.nih.gov/26487582/
496.Albers, P., et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol, 2011. 22: 288.
https://pubmed.ncbi.nlm.nih.gov/20682548/
497.Fechner, G., et al. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract, 2006. 60: 27.
https://pubmed.ncbi.nlm.nih.gov/16409425/
498.Bellmunt, J., et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol, 2009. 27: 4454.
https://pubmed.ncbi.nlm.nih.gov/19687335/
499.Petrylak, D.P., et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet, 2017. 390: 2266.
https://pubmed.ncbi.nlm.nih.gov/28916371/
500.Petrylak, D.P., et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol, 2020. 21: 105.
https://pubmed.ncbi.nlm.nih.gov/31753727/
501.Bellmunt, J., et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
N Engl J Med, 2017. 376: 1015.
https://pubmed.ncbi.nlm.nih.gov/28212060/
502.Powles, T., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 2014. 515: 558.
https://pubmed.ncbi.nlm.nih.gov/25428503/
503.Powles, T., et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2018. 391: 748.
https://pubmed.ncbi.nlm.nih.gov/29268948/
504.Sharma, P., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol, 2017. 18: 312.
https://pubmed.ncbi.nlm.nih.gov/28131785/
505.Postow, M.A., et al. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med, 2018. 378: 158.
https://pubmed.ncbi.nlm.nih.gov/29320654/
506.Brahmer, J.R., et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 2018. 36: 1714.
https://pubmed.ncbi.nlm.nih.gov/29442540/
507.Maher, V.E., et al. Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. J Clin Oncol, 2019. 37: 2730.
https://pubmed.ncbi.nlm.nih.gov/31116675/
508.Rosenberg, J.E., et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol, 2019. 37: 2592.
https://pubmed.ncbi.nlm.nih.gov/31356140/
509.Chang, E., et al. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res, 2021. 27: 922.
https://pubmed.ncbi.nlm.nih.gov/32962979/
510.European Medicines Agency. Padcev - enfortumab vedotin. Access date December 2022.
https://www.ema.europa.eu/en/documents/overview/padcev-epar-medicine-overview_nl.pdf
511.Yu, E.Y., et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol, 2021. 22: 872.
https://pubmed.ncbi.nlm.nih.gov/33991512/
512.Powles, T., et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl
J Med, 2021. 384: 1125.
https://pubmed.ncbi.nlm.nih.gov/33577729/
513.Hoimes, C.J., et al. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. J Clin Oncol, 2022: Jco2201643.
https://pubmed.ncbi.nlm.nih.gov/36041086/
514.Tagawa, S.T., et al. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol, 2021. 39: 2474.
https://pubmed.ncbi.nlm.nih.gov/33929895/
515.Robertson, A.G., et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 2018. 174: 1033.
https://pubmed.ncbi.nlm.nih.gov/30096301/
516.Siefker-Radtke, A.O., et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol, 2022. 23: 248.
https://pubmed.ncbi.nlm.nih.gov/35030333/
517.Birtle, A., et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet, 2020. 395: 1268.
https://pubmed.ncbi.nlm.nih.gov/32145825/
518.Coleman, R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev, 2001. 27: 165.
https://pubmed.ncbi.nlm.nih.gov/11417967/
519.Rosiello, G., et al. Sex- and age-related differences in the distribution of bladder cancer metastases. Jpn J Clin Oncol, 2021. 51: 976.
https://pubmed.ncbi.nlm.nih.gov/33558890/
520.Aapro, M., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol, 2008. 19: 420.
https://pubmed.ncbi.nlm.nih.gov/17906299/
521.Zaghloul, M.S., et al. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol, 2010. 15: 382.
https://pubmed.ncbi.nlm.nih.gov/20354750/
522.Henry, D.H., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol, 2011. 29: 1125.
https://pubmed.ncbi.nlm.nih.gov/21343556/
523.Rosen, L.S., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer, 2004. 100: 2613.
https://pubmed.ncbi.nlm.nih.gov/15197804/
524.Smith, A.B., et al. Impact of bladder cancer on health-related quality of life. BJU Int, 2018. 121: 549.
https://pubmed.ncbi.nlm.nih.gov/28990272/
525.Smith, A.B., et al. Quality of Life and Health State Utilities in Bladder Cancer. Bladder Cancer, 2022. 8: 55.
https://content.iospress.com/articles/bladder-cancer/blc211615
526.Cella, D.F., et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol, 1993. 11: 570.
https://pubmed.ncbi.nlm.nih.gov/8445433/
527.Aaronson, N.K., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 1993. 85: 365.
https://pubmed.ncbi.nlm.nih.gov/8433390/
528.Ware, J.E., Jr., et al. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care, 1992. 30: 473.
https://pubmed.ncbi.nlm.nih.gov/1593914/
529.Gilbert, S.M., et al. Development and validation of the Bladder Cancer Index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer.
J Urol, 2010. 183: 1764.
https://pubmed.ncbi.nlm.nih.gov/20299056/
530.Bessa, A., et al. Unmet needs in sexual health in bladder cancer patients: a systematic review of the evidence. BMC Urol, 2020. 20: 64.
https://pubmed.ncbi.nlm.nih.gov/32493286/
531.Westhofen, T., et al. Baseline Health-related Quality of Life Predicts Bladder Cancer-specific Survival Following Radical Cystectomy. Eur Urol Focus, 2022. 8: 1659.
https://pubmed.ncbi.nlm.nih.gov/35184991/
532.Kitamura, H., et al. Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle-invasive bladder cancer: results from JCOG0209, a randomized phase III study. Jpn
J Clin Oncol, 2020. 50: 1464.
https://pubmed.ncbi.nlm.nih.gov/32699909/
533.Cerruto, M.A., et al. Systematic review and meta-analysis of non RCT’s on health related quality of life after radical cystectomy using validated questionnaires: Better results with orthotopic neobladder versus ileal conduit. Eur J Surg Oncol, 2016. 42: 343.
https://pubmed.ncbi.nlm.nih.gov/26620844/
534.Mastroianni, R., et al. Comparison of Patient-reported Health-related Quality of Life Between Open Radical Cystectomy and Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Interim Analysis of a Randomised Controlled Trial. Eur Urol Focus, 2022. 8: 465.
https://pubmed.ncbi.nlm.nih.gov/33712389/
535.Becerra, M.F., et al. Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy.
J Urol, 2020. 204: 450.
https://pubmed.ncbi.nlm.nih.gov/32271690/
536.Fossa, S.D., et al. Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistant prostatic cancer. Eur Urol, 1989. 16: 335.
https://pubmed.ncbi.nlm.nih.gov/2476317/
537.Nagele, U., et al. The rationale for radical cystectomy as primary therapy for T4 bladder cancer. World J Urol, 2007. 25: 401.
https://pubmed.ncbi.nlm.nih.gov/17525849/
538.Fokdal, L., et al. Radical radiotherapy for urinary bladder cancer: treatment outcomes. Expert Rev Anticancer Ther, 2006. 6: 269.
https://pubmed.ncbi.nlm.nih.gov/16445379/
539.Rodel, C., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol, 2002. 20: 3061.
https://pubmed.ncbi.nlm.nih.gov/12118019/
540.Vaughn, D.J., et al. Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. J Clin Oncol, 2018. 36: 1579.
https://pubmed.ncbi.nlm.nih.gov/29590008/
541.McGregor, B., et al. Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. Eur Urol, 2022. 81: 515.
https://pubmed.ncbi.nlm.nih.gov/35168844/
542.Malkowicz, S.B., et al. Muscle-invasive urothelial carcinoma of the bladder. Urology, 2007. 69: 3.
https://pubmed.ncbi.nlm.nih.gov/17280906/
543.Karakiewicz, P.I., et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol, 2006. 176: 1354.
https://pubmed.ncbi.nlm.nih.gov/16952631/
544.Zaak, D., et al. Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. BJU Int, 2010. 106: 342.
https://pubmed.ncbi.nlm.nih.gov/20002664/
545.Giannarini, G., et al. Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol, 2010. 58: 486.
https://pubmed.ncbi.nlm.nih.gov/20541311/
546.Volkmer, B.G., et al. Oncological followup after radical cystectomy for bladder cancer-is there any benefit? J Urol, 2009. 181: 1587.
https://pubmed.ncbi.nlm.nih.gov/19233433/
547.Boorjian, S.A., et al. Detection of asymptomatic recurrence during routine oncological followup after radical cystectomy is associated with improved patient survival. J Urol, 2011. 186: 1796.
https://pubmed.ncbi.nlm.nih.gov/21944088/
548.Soukup, V., et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol, 2012. 62: 290.
https://pubmed.ncbi.nlm.nih.gov/22609313/
549.Huguet, J. Follow-up after radical cystectomy based on patterns of tumour recurrence and its risk factors. Actas Urol Esp, 2013. 37: 376.
https://pubmed.ncbi.nlm.nih.gov/23611464/
550.Ghoneim, M.A., et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol, 2008. 180: 121.
https://pubmed.ncbi.nlm.nih.gov/18485392/
551.Donat, S.M. Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective? World J Urol, 2006. 24: 557.
https://pubmed.ncbi.nlm.nih.gov/17009050/
552.Mathers, M.J., et al. Is there evidence for a multidisciplinary follow-up after urological cancer? An evaluation of subsequent cancers. World J Urol, 2008. 26: 251.
https://pubmed.ncbi.nlm.nih.gov/18421461/
553.Vrooman, O.P., et al. Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice. Curr Opin Urol, 2010. 20: 437.
https://pubmed.ncbi.nlm.nih.gov/20657286/
554.Cagiannos, I., et al. Surveillance strategies after definitive therapy of invasive bladder cancer. Can Urol Assoc J, 2009. 3: S237.
https://pubmed.ncbi.nlm.nih.gov/20019993/
555.Bekku, K., et al. Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma? Int J Clin Oncol, 2013. 18: 110.
https://pubmed.ncbi.nlm.nih.gov/22095246/
556.Lehmann, J., et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol, 2009. 55: 1293.
https://pubmed.ncbi.nlm.nih.gov/19058907/
557.Fahmy, O., et al. Urethral recurrence after radical cystectomy for urothelial carcinoma: A systematic review and meta-analysis. Urol Oncol, 2018. 36: 54.
https://pubmed.ncbi.nlm.nih.gov/29196179/
558.Varol, C., et al. Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution. J Urol, 2004. 172: 937.
https://pubmed.ncbi.nlm.nih.gov/15311003/
559.Gakis, G., et al. Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. Eur Urol, 2017. 71: 545.
https://pubmed.ncbi.nlm.nih.gov/27720534/
560.Picozzi, S., et al. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J Urol, 2012. 188: 2046.
https://pubmed.ncbi.nlm.nih.gov/23083867/
561.Sanderson, K.M., et al. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol, 2007.
177: 2088.
https://pubmed.ncbi.nlm.nih.gov/17509294/
562.Stewart-Merrill, S.B., et al. Evaluation of current surveillance guidelines following radical cystectomy and proposal of a novel risk-based approach. Urol Oncol, 2015. 33: 339.e1.
https://pubmed.ncbi.nlm.nih.gov/26031371/
563.Martini, A., et al. Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy. J Urol, 2021. 206: 885.
https://pubmed.ncbi.nlm.nih.gov/34032498/
564.Gupta, A., et al. Risk of fracture after radical cystectomy and urinary diversion for bladder cancer.
J Clin Oncol, 2014. 32: 3291.
https://pubmed.ncbi.nlm.nih.gov/25185104/
565.Madersbacher, S., et al. Long-term outcome of ileal conduit diversion. J Urol, 2003. 169: 985.
https://pubmed.ncbi.nlm.nih.gov/12576827/
566.Shah, S.H., et al. Ureteroenteric Strictures After Open Radical Cystectomy and Urinary Diversion: The University of Southern California Experience. Urology, 2015. 86: 87.
https://pubmed.ncbi.nlm.nih.gov/25987494/
567.Nieuwenhuijzen, J.A., et al. Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions. Eur Urol, 2008. 53: 834.
https://pubmed.ncbi.nlm.nih.gov/17904276/
568.Schmidt, B., et al. Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer. Eur Urol Open Sci, 2022. 35: 29.
https://pubmed.ncbi.nlm.nih.gov/35024629/
569.Wood, D.N., et al. Stomal complications of ileal conduits are significantly higher when formed in women with intractable urinary incontinence. J Urol, 2004. 172: 2300.
https://pubmed.ncbi.nlm.nih.gov/15538253/
570.Neal, D.E. Complications of ileal conduit diversion in adults with cancer followed up for at least five years. Br Med J (Clin Res Ed), 1985. 290: 1695.
https://pubmed.ncbi.nlm.nih.gov/3924218/
571.Shimko, M.S., et al. Long-term complications of conduit urinary diversion. J Urol, 2011. 185: 562.
https://pubmed.ncbi.nlm.nih.gov/21168867/
572.Clifford, T.G., et al. Prospective Evaluation of Continence Following Radical Cystectomy and Orthotopic Urinary Diversion Using a Validated Questionnaire. J Urol, 2016. 196: 1685.
https://pubmed.ncbi.nlm.nih.gov/27256205/
573.Bartsch, G., et al. Urinary functional outcomes in female neobladder patients. World J Urol, 2014. 32: 221.
https://pubmed.ncbi.nlm.nih.gov/24317553/
574.Stenzl, A., et al. Urethra-sparing cystectomy and orthotopic urinary diversion in women with malignant pelvic tumors. Cancer, 2001. 92: 1864.
https://pubmed.ncbi.nlm.nih.gov/11745259/
575.Hautmann, R.E., et al. Functional Outcome and Complications following Ileal Neobladder Reconstruction in Male Patients without Tumor Recurrence. More than 35 Years of Experience from a Single Center. J Urol, 2021. 205: 174.